MIM
RXRX icon

MetLife Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

MetLife Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$772K Buy
251,512
+41,711
+20% +$161K ﹤0.01% 1533
2025
Q4 		$858K Sell
209,801
-5,439
-3% -$26.9K ﹤0.01% 1516
2025
Q3 		$1.05M Buy
215,240
+11,160
+5% +$58.6K 0.01% 1421
2025
Q2 		$1.03M Buy
204,080
+56,073
+38% +$275K 0.01% 1297
2025
Q1 		$783K Sell
148,007
-1,801
-1% -$13.1K ﹤0.01% 1483
2024
Q4 		$1.01M Buy
149,808
+13,267
+10% +$89.2K 0.01% 1407
2024
Q3 		$900K Buy
136,541
+16,405
+14% +$118K 0.01% 1453
2024
Q2 		$901K Buy
120,136
+47,975
+66% +$418K 0.01% 1399
2024
Q1 		$719K Hold
72,161
– – ﹤0.01% 1485
2023
Q4 		$712K Hold
72,161
– – 0.01% 1491
2023
Q3 		$552K Hold
72,161
– – ﹤0.01% 1571
2023
Q2 		$539K Hold
72,161
– – ﹤0.01% 1649
2023
Q1 		$481K Hold
72,161
– – ﹤0.01% 1670
2022
Q4 		$556K Hold
72,161
– – ﹤0.01% 1574
2022
Q3 		$768K Hold
72,161
– – 0.01% 1328
2022
Q2 		$587K Buy
72,161
+8,126
+13% +$54.4K ﹤0.01% 1551
2022
Q1 		$458K Buy
64,035
+22,833
+55% +$243K ﹤0.01% 1826
2021
Q4 		$706K Buy
41,202
+30,451
+283% +$573K 0.01% 1302
2021
Q3 		$247K Buy
10,751
+2,043
+23% +$57.9K ﹤0.01% 1953
2021
Q2 		$318K Buy
+8,708
New +$258K ﹤0.01% 1848

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's RXRX Position: Q1 2026 in Review

MetLife Investment Management increased its Recursion Pharmaceuticals (RXRX) stake by 20% in Q1 2026, buying an estimated $161K and bringing the position to 251,512 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

MetLife Investment Management first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.05M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • MetLife Investment Management held 251,512 shares of Recursion Pharmaceuticals worth $772K as of Q1 2026.
  • MetLife Investment Management bought 41,711 Recursion Pharmaceuticals shares in Q1 2026, an estimated $161K.
  • Recursion Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1533 holding.
  • MetLife Investment Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • MetLife Investment Management's Recursion Pharmaceuticals position peaked at $1.05M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.